Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant

Surakit Pungpapong, Bashar Aqel, Michael Leise, K. Tuesday Werner, Jennifer L. Murphy, Tanisha M. Henry, Kristen Ryland, Amy E. Chervenak, Kymberly D. Watt, Hugo E. Vargas, Andrew P. Keaveny – 26 February 2015 – Treatment with an all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir with or without ribavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along with minimal adverse events in non–liver transplant (LT) patients with hepatitis C virus (HCV) genotype 1 infection.

Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4‐phenylbutyrate

Emmanuel Gonzales, Brigitte Grosse, Brice Schuller, Anne Davit‐Spraul, Filomena Conti, Catherine Guettier, Doris Cassio, Emmanuel Jacquemin – 26 February 2015 – Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a result of mutations in ABCB11 encoding bile salt export pump (BSEP), the canalicular bile salt export pump of hepatocyte. In some PFIC2 patients with missense mutations, BSEP is not detected at the canaliculus owing to mistrafficking of BSEP mutants. In vitro, chaperone drugs, such as 4‐phenylbutyrate (4‐PB), have been shown to partially correct mistrafficking.

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant

Surakit Pungpapong, Bashar Aqel, Michael Leise, K. Tuesday Werner, Jennifer L. Murphy, Tanisha M. Henry, Kristen Ryland, Amy E. Chervenak, Kymberly D. Watt, Hugo E. Vargas, Andrew P. Keaveny – 26 February 2015 – Treatment with an all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir with or without ribavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along with minimal adverse events in non–liver transplant (LT) patients with hepatitis C virus (HCV) genotype 1 infection.

A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial–mesenchymal transition–independent manner

Jian‐Hong Fang, Hui‐Chao Zhou, Chong Zhang, Li‐Ru Shang, Lei Zhang, Jing Xu, Limin Zheng, Yunfei Yuan, Rong‐Ping Guo, Wei‐Hua Jia, Jing‐Ping Yun, Min‐Shan Chen, Yaojun Zhang, Shi‐Mei Zhuang – 24 February 2015 – Early metastasis is responsible for frequent relapse and high mortality of hepatocellular carcinoma (HCC), but its underlying mechanisms remain unclear. Epithelial–mesenchymal transition (EMT) has been considered a key event in metastasis.

Drug‐induced allergic hepatitis develops in mice when myeloid‐derived suppressor cells are depleted prior to halothane treatment

Mala Chakraborty, Aaron M. Fullerton, Kenrick Semple, Lynette S. Chea, William R. Proctor, Mohammed Bourdi, David E. Kleiner, Xiangbin Zeng, Pauline M. Ryan, Pradeep K. Dagur, Julia D. Berkson, Timothy P. Reilly, Lance R. Pohl – 24 February 2015 – Clinical evidence suggests that many cases of serious idiosyncratic drug‐induced liver injury are mediated by the adaptive immune system in response to hepatic drug‐protein adducts, also referred to as “drug‐induced allergic hepatitis”; but detailed mechanistic proof has remained elusive due to the lack of animal models.

A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial–mesenchymal transition–independent manner

Jian‐Hong Fang, Hui‐Chao Zhou, Chong Zhang, Li‐Ru Shang, Lei Zhang, Jing Xu, Limin Zheng, Yunfei Yuan, Rong‐Ping Guo, Wei‐Hua Jia, Jing‐Ping Yun, Min‐Shan Chen, Yaojun Zhang, Shi‐Mei Zhuang – 24 February 2015 – Early metastasis is responsible for frequent relapse and high mortality of hepatocellular carcinoma (HCC), but its underlying mechanisms remain unclear. Epithelial–mesenchymal transition (EMT) has been considered a key event in metastasis.

Subscribe to